focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.75
Bid: 26.50
Ask: 27.00
Change: -0.75 (-2.73%)
Spread: 0.50 (1.887%)
Open: 27.50
High: 27.50
Low: 26.75
Prev. Close: 27.50
HVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

7 Jan 2013 07:00

RNS Number : 8624U
Retroscreen Virology Group PLC
07 January 2013
 



For immediate release 07.00: 7 January 2013

 

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

 

CONTRACT WIN

 

Retroscreen Virology Group plc (AIM: RVG), the viral challenge and "Virometrics" specialist, is pleased to announce the signing of a Viral Challenge Model ("VCM") contract for evaluating modes of influenza transmission and better understanding how flu is spread.

 

The study will be the largest ever investigation into influenza transmission and is a collaboration with the University of Nottingham and other international groups, funded by the United States Centers for Disease Control and Prevention (CDC). The contract is valued at £3.9 million and the study will commence in H1 2013.

 

Kym Denny, Chief Executive Officer, commented, "The spread of influenza virus is surprisingly poorly understood and this is vital research. Even before the next pandemic, respiratory illness in general and flu in particular is one of the largest drivers of cost to health provision in the developed world. The funding by the CDC illustrates the continuing importance of influenza research and further demonstrates the flexibility and application of the VCM for research-based projects, as well as studies involving new antiviral drugs and vaccines. We are delighted to be working with the University of Nottingham again, with whom we have previously established the transmission model. We are tremendously excited by the study which will help us better understand how to prevent the spread of flu and inform future public health initiatives."

 

 

 

For further information please contact:

 

Retroscreen Virology Group plc +44 207 756 1300

 

Kym Denny (CEO)

Graham Yeatman (FD)

 

Numis Securities Limited +44 207 260 1000

 

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRANKQDNDBKDBDK
Date   Source Headline
16th Oct 20199:49 amRNSHolding(s) in Company
3rd Oct 20199:51 amRNSDirector's Dealings
2nd Oct 20195:03 pmRNSExercise of Share Options
27th Sep 20197:00 amRNShVIVO to present at ERS International Congress
19th Sep 20197:00 amRNSInterim Results 2019
23rd Aug 20197:00 amRNSNotice of Interim Results
6th Aug 20197:00 amRNSSuccessful RSV Challenge Study in Older Adults
31st Jul 20197:00 amRNSPhase 1 clinical trial of AGS-v PLUS
31st Jul 20197:00 amRNSFinance Director
25th Jul 20193:15 pmRNSExercise of Share Options
25th Jul 20193:10 pmRNSExercise of Share Options
16th Jul 20197:00 amRNSExercise of Share Options
9th Jul 20194:00 pmRNSHolding(s) in Company
9th Jul 201911:00 amRNSHolding(s) in Company
2nd Jul 20191:45 pmRNSDirector's Dealings
26th Jun 20194:10 pmRNSExercise of Share Options
17th Jun 20197:00 amRNSRSV Challenge Model Delivers Positive Results
14th Jun 201912:00 pmRNSExercise of Share Options
31st May 201912:00 pmRNSResult of AGM
21st May 20197:00 amRNSExercise of Share Options
26th Apr 20199:56 amRNS2018 Annual Report and Financial Statements
11th Apr 20197:00 amRNSPreliminary Results 2018
1st Apr 20191:21 pmRNSDirector's Dealings
29th Mar 20197:00 amRNShVIVO and Imutex to present at IVW 2019
21st Mar 201910:34 amRNSExercise of Share Options
8th Mar 20197:00 amRNSNotice of Preliminary Results
30th Jan 20199:55 amRNSHolding(s) in Company
24th Jan 201910:12 amRNSShare Incentive Plan and PDMR Dealings
10th Jan 20197:00 amRNSPositive data for Phase IIb FLU-v challenge study
4th Jan 20194:00 pmRNSDirector's Dealings
4th Jan 201910:02 amRNSAward of Share Options
2nd Jan 20197:00 amRNSDirectorate Change
20th Nov 20187:00 amRNSExercise of Share Options
31st Oct 20187:00 amRNSPartial preliminary results for NIH study of AGS-v
8th Oct 20182:00 pmRNSDirector's Dealings
8th Oct 20187:02 amRNSTwo new contracts for RSV human challenge studies
8th Oct 20187:00 amRNSDirectorate Change
1st Oct 20187:00 amRNSNotification of Major Holdings
28th Sep 201811:00 amRNSNotification of Major Holdings
20th Sep 20187:00 amRNSHalf-year Report
18th Sep 20187:00 amRNSExercise of Share Options
10th Sep 20187:00 amRNSNotification of Major Interest in Shares
29th Aug 20182:00 pmRNSNotification of Major Interest in Shares
29th Aug 20187:00 amRNSNotification of Major Interest in Shares
21st Aug 201811:00 amRNSExercise of Share Options
20th Aug 20187:00 amRNSNotification of Major Interest in Shares
16th Aug 20187:00 amRNSNotice of Interim Results
13th Aug 20187:00 amRNSAward of Share Options
10th Aug 20187:00 amRNSDirector's Dealings
10th Aug 20187:00 amRNSExercise of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.